Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

被引：152

作者：

Bunck, Mathijs C. ^{[1
]}

Diamant, Michaela ^{[1
]}

Eliasson, Bjorn ^{[2
]}

Corner, Anja ^{[3
,4
]}

Shaginian, Rimma M. ^{[5
]}

Heine, Robert J. ^{[1
,6
]}

Taskinen, Marja-Riitta ^{[3
]}

Yki-Jarvinen, Hannele ^{[3
]}

Smith, Ulf ^{[2
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, Dept Internal Med,Sect Endocrinol, Amsterdam, Netherlands

[2] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, Gothenburg, Sweden

[3] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland

[4] Minerva Med Res Inst, Helsinki, Finland

[5] Eli Lilly & Co, Houten, Netherlands

[6] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

DIABETES CARE | 2010年 / 33卷 / 08期

关键词：

INSULIN GLARGINE; PEPTIDE-1; ANALOG; FAT; EXENDIN-4; LIRAGLUTIDE; METFORMIN;

D O I：

10.2337/dc09-2361

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

OBJECTIVE To study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND METHODS Metformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured. RESULTS Treatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight. CONCLUSIONS Exenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.

引用

页码：1734 / 1737

页数：4

共 15 条

[1]

One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].

Bunck, Mathijs C. ;

Diamant, Michaela ;

Corner, Anja ;

Eliasson, Bjorn ;

Malloy, Jaret L. ;

Shaginian, Rimma M. ;

Deng, Wei ;

Kendall, David M. ;

Taskinen, Marja-Riitta ;

Smith, Ulf ;

Yki-Jarvinen, Hannele ;

Heine, Robert J. .

DIABETES CARE, 2009, 32 (05) :762-768

[2]

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression [J].

Chung, Le Thi Kim ;

Hosaka, Toshio ;

Yoshida, Masaki ;

Harada, Nagakatsu ;

Sakaue, Hiroshi ;

Sakai, Tohru ;

Nakaya, Yutaka .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 390 (03) :613-618

[3]

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes [J].

Courreges, J. -P. ;

Vilsboll, T. ;

Zdravkovic, M. ;

Le-Thi, T. ;

Krarup, T. ;

Schmitz, O. ;

Verhoeven, R. ;

Buganova, I. ;

Madsbad, S. .

DIABETIC MEDICINE, 2008, 25 (09) :1129-1131

[4]

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].

DeFronzo, Ralph A. .

DIABETES, 2009, 58 (04) :773-795

[5]

The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes [J].

Diamant, M ;

Lamb, HJ ;

van de Ree, MA ;

Endert, EL ;

Groeneveld, Y ;

Bots, ML ;

Kostense, PJ ;

Radder, JK .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1495-1501

[6]

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice [J].

Ding, XK ;

Saxena, NK ;

Lin, SB ;

Gupta, N ;

Anania, FA .

HEPATOLOGY, 2006, 43 (01) :173-181

[7]

Horton ES, 2009, DIABETOLOGIA, V52, pS298

[8]

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue [J].

Jendle, J. ;

Nauck, M. A. ;

Matthews, D. R. ;

Frid, A. ;

Hermansen, K. ;

During, M. ;

Zdravkovic, M. ;

Strauss, B. J. ;

Garber, A. J. .

DIABETES OBESITY & METABOLISM, 2009, 11 (12) :1163-1172

[9]

Role of Body Fat Distribution and the Metabolic Complications of Obesity [J].

Jensen, Michael D. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (11) :S57-S63

[10]

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment [J].

Kim, Wook ;

Egan, Josephine M. .

PHARMACOLOGICAL REVIEWS, 2008, 60 (04) :470-512

← 1 2 →